Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2652W HIGH $5.56
Volume
14.90 K
Value Traded
41.52 K
Short % Float
0.66%
-11.72%Week
+981.39%1 Month
+816.47%3 Month
+1,126.45%6 Month
-89.55%5 Year
-98.96%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
565.91 M
EPS (TTM)
-0.37
P/E Ratio
-
Ent. Value
-2.31 M
Total Shares
147.37 M
Float Shares
7.31 M
Insiders
0.84%
Institutions
1.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IMMP Catalyst Timeline
Dated clinical, regulatory and corporate events for Immutep Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immutep Limited
1391Total events
8Upcoming
262Tier-1 (high impact)
2012 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Grant / FundingCorporate
Immutep receives first payment under Germany's Forschungszulage R&D tax incentive program
▲Grant / FundingCorporate
Immutep receives A$856,669 R&D tax incentive rebate from Australian Federal Government
▲Patent Grantedeftilagimod alfa (efti / IMP321)IP / Competition
USPTO grants fourth US patent for eftilagimod alfa in combination with PD-1 pathway inhibitors
cancersource ↗
▲Full Resultseftilagimod alfa (efti / IMP321)Clinical Data
Mature mOS of 30.9 months in overall population and TPS<50% subgroup from INSIGHT-003
1st line non-squamous non-small cell lung cancersource ↗
◆Additional Dataeftilagimod alfa (efti / IMP321)Clinical Data
Additional root cause analysis results expected
1st line non-small cell lung cancersource ↗
◆Timing Guidanceeftilagimod alfa (efti / IMP321)Presentation
Root cause analysis update expected in Q3 CY26
non-small cell lung cancersource ↗
▲Full Resultseftilagimod alfa (efti / IMP321)Clinical Data
Mature OS results from INSIGHT-003 reported
non-small cell lung cancersource ↗
▼Interim Analysiseftilagimod alfa (efti / IMP321)Trial
TACTI-004 interim futility analysis results reported
non-small cell lung cancersource ↗
▼Trial Pausedeftilagimod alfa (efti / IMP321)Trial
Neoadjuvant efti breast cancer trial on hold
breast cancersource ↗
●Trial Completioneftilagimod alfa (efti / IMP321)Trial
AIPAC-003 completed and closed
metastatic breast cancersource ↗
▼Trial Pausedeftilagimod alfa (efti / IMP321)Trial
Neoadjuvant efti trial on hold pending root cause analysis
breast cancersource ↗
▲Primary Endpoint Meteftilagimod alfa (efti / IMP321)Clinical Data
EFTISARC-NEO met primary objective
soft tissue sarcomasource ↗
●Milestone Paymenteftilagimod alfa (efti / IMP321)Corporate
Dr. Reddy's license fee received and partially repaid
◆Poster PresentationIMP761Presentation
IMP761 Phase I data to be presented at EULAR 2026
Autoimmune diseasessource ↗
▲Primary Endpoint MetIMP761Clinical Data
Phase I single ascending dose part met primary endpoint of safety and tolerability
autoimmune diseasessource ↗
●Oral PresentationIMP761Presentation
Presentation of IMP761 details at EULAR 2026 Congress
autoimmune diseasessource ↗
●Milestone Paymenteftilagimod alfa (efti / IMP321)Corporate
Dr. Reddy's license fee partially repaid
▲Oral PresentationIMP761Presentation
IMP761 first-in-human results presented at EULAR 2026
autoimmune diseasesource ↗
●Trial Completioneftilagimod alfa (efti / IMP321)Trial
INSIGHT-003 dosing complete
Non-squamous 1L NSCLCsource ↗
▼Trial Pausedeftilagimod alfa (efti / IMP321)Trial
Neoadjuvant efti trial on hold pending root cause analysis
HR+/HER2-negative breast cancersource ↗
▲Patent GrantedIMP761IP / Competition
Patents granted for IMP761 potency assay and composition
▲Patent GrantedieramilimabIP / Competition
Patents granted for LAG525 (ieramilimab) in US and Israel
▲Interim AnalysisIMP761Trial
IMP761 Phase I interim data presented at EULAR 2026
autoimmune diseasesource ↗
▲Primary Endpoint MetIMP761Clinical Data
IMP761 Phase I met primary safety endpoint
autoimmune diseasesource ↗
◆Poster Presentationeftilagimod alfa (efti / IMP321)Presentation
Poster presentation at ASCO 2026: Efti induced lymphocyte activation linked to improved survival
late-stage cancer (NSCLC, HNSCC, MBC, melanoma)source ↗
▲Full Resultseftilagimod alfa (efti / IMP321)Clinical Data
Systematic evaluation of 5 trials shows efti + SOC improves OS in ALC responders
late-stage cancer (NSCLC, HNSCC, MBC, melanoma)source ↗
▲Poster Presentationeftilagimod alfa (efti / IMP321)Presentation
Pooled analysis of five efti trials presented at ASCO 2026
cancersource ↗
▼Trial Discontinuedeftilagimod alfa (efti / IMP321)Trial
TACTI-004 Phase III trial discontinued following IDMC recommendation after interim futility analysis
first-line non-small cell lung cancersource ↗
▼Enrollment Pausedeftilagimod alfa (efti / IMP321)Trial
Enrollment halted in TACTI-004 due to trial discontinuation
first-line non-small cell lung cancersource ↗
▼Restructuring LayoffsCorporate
Cost reduction measures including targeted headcount reduction initiated
▼Trial Pausedeftilagimod alfa (efti / IMP321)Trial
Proposed investigator-initiated Phase II trial for neoadjuvant efti in breast cancer on hold
early-stage HR+/HER2-negative breast cancersource ↗
▼Timing GuidancePresentation
Immutep received Nasdaq notification of non-compliance with minimum bid price requirement
▲Orphan Drug Designationeftilagimod alfa (efti / IMP321)Designation
FDA grants Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma
Soft Tissue Sarcomasource ↗
▲Orphan Drug Designationeftilagimod alfa (efti / IMP321)Designation
FDA granted orphan drug designation for efti in STS
soft tissue sarcomasource ↗
▲Primary Endpoint Meteftilagimod alfa (efti / IMP321)Clinical Data
EFTISARC-NEO met primary objective
soft tissue sarcomasource ↗
▼Restructuring LayoffsCorporate
Targeted headcount reduction and cost reduction measures initiated
▼Interim Analysiseftilagimod alfa (efti / IMP321)Trial
Planned interim futility analysis conducted by IDMC
first-line non-small cell lung cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How IMMP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | eftilagimod alfa (efti) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$569M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
0.9x
rNPV / MCap
Top 22%
Micro Cap(rank 146 of 658)
Percentile Rank
Immutep Limited carries a moderate pipeline score (48/100), with $1.8B risk-adjusted pipeline value, led by eftilagimod alfa (efti / IMP321) in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (Phase 3), across $101B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| eftilagimod alfa (efti / IMP321) Monoclonal antibodyNCT06726265 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | ACTIVE NOT_RECRUITING | 756 | Sep 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMMP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| eftilagimod alfa Fast TrackOrphan | 1st line non-small cell lung cancer (1L NSCLC) | Phase 3 | 2026-07-30 | median overall survival benefit: 7.7 months; objective response rate efti arm: 42.9%; objective response rate control arm: 55.1%Read More | Immutep Quarterly Activities Report Q4 FY26Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMMP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Boxer Capital Management, LLC | 0.3 % | 9.68 M | 2.50 M |
IMMP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMMP ranks across every disease it competes in
Competitive Position is a premium feature
See how IMMP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMMP News
IMMPImmutep Receives ~A$0.86 Million R&D Tax Incentive
Immutep Limited has secured an A$856,669 cash rebate from the Australian government's R&D tax incentive program for eligible activities in the 2025 fiscal year. The company is also eligible for R&D tax incentives in France and Germany, which will support its ongoing research into product candidates efti and IMP761. However, the timing and amount of future payments remain uncertain due to regulatory processes.
Read more →IMMPChange to American Depositary Share Ratio
Immutep Limited announced a change in the ratio of its American Depositary Shares (ADSs) from 1:10 to 1:200, effective September 28, 2026. This adjustment is a strategic move to comply with Nasdaq's minimum bid price requirement after the ADSs traded below $1.00 for 30 consecutive days. The change does not impact the number of ordinary shares or the company’s capital structure.
Read more →IMMP▲ +14.8%on this news
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
Immutep Limited has outlined a focused development strategy for eftilagimod alfa, targeting head and neck squamous cell carcinoma and soft tissue sarcoma. The company has contracted a new manufacturing run to address issues identified in the TACTI-004 study. Preparations for future clinical trials are underway, with a targeted start in the second half of 2027.
Read more →IMMPImmutep Quarterly Activities Report Q4 FY26
Immutep Limited reported positive developments in its quarterly activities for Q4 FY26, highlighting a pooled analysis of efti trials that demonstrated a 7.7-month survival benefit. The company also shared promising results from its IMP761 trial, while addressing the discontinuation of the TACTI-004 trial due to futility. Financially, Immutep remains strong with significant cash reserves.
Read more →IMMPImmutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Immutep Limited announced that an abstract for the EFTISARC-NEO Phase II trial has been accepted for presentation at the ESMO Congress 2026 in Madrid. The abstract will feature health-related quality of life data regarding their first-in-class MHC Class II agonist, eftilagimod alfa. The full abstract will be published on the ESMO website on October 19, 2026.
Read more →IMMPImmutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
Immutep Limited has secured a fourth U.S. patent for its immunotherapy, eftilagimod alfa, which is designed for cancer treatment in combination with PD-1 pathway inhibitors. This new patent enhances the company's intellectual property portfolio, supporting future development and business opportunities. Eftilagimod alfa is currently being evaluated for various solid tumors and has received Fast Track designation from the FDA.
Read more →IMMP▲ +7.5%on this newsshared move
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
Immutep announced positive results from the INSIGHT-003 Phase I trial, showing a median overall survival of 30.9 months in patients with non-squamous NSCLC. The results are particularly encouraging for patients with low PD-L1 expression, who typically have fewer treatment options. However, the TACTI-004 trial was discontinued after a futility analysis indicated inferior outcomes compared to the control arm.
Read more →IMMPImmutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
Immutep Limited announced positive interim Phase I data for its LAG-3 agonist antibody, IMP761, which showed favorable safety and pharmacodynamic activity in healthy volunteers. The study met its primary endpoint and demonstrated significant immunosuppressive effects, supporting further clinical investigation in autoimmune diseases. Additional updates are expected in H2 CY2026.
Read more →IMMPSystemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
Immutep Limited announced positive results from five clinical trials evaluating eftilagimod alfa in late-stage cancer patients. The combination of eftilagimod alfa with standard-of-care therapies led to a significant increase in overall survival, particularly among patients showing an immune response. The findings suggest a strong link between immune activation and improved clinical outcomes across various cancer types.
Read more →IMMP▼ -5.6%on this news
Immutep Quarterly Activities Report & Appendix 4C Q3 FY26
Immutep has decided to discontinue the TACTI-004 Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer based on a recommendation from the Independent Data Monitoring Committee. The interim futility analysis indicated that patients receiving the treatment were underperforming compared to those on a placebo. Although this outcome was disappointing, Immutep continues to explore other avenues for its clinical programs, including ongoing trials like INSIGHT-003, which show favorable results. The company's financial position remains solid with a cash balance of approximately A$110.6 million.
Read more →IMMPImmutep Quarterly Activities Report Q3 FY26
Immutep Limited has announced the discontinuation of its TACTI-004 Phase III trial following an interim futility analysis by the Independent Data Monitoring Committee. The analysis revealed that patients receiving the combination of eftilagimod alfa, KEYTRUDA, and chemotherapy were underperforming compared to the control group. Despite this setback, the company reported a strong cash position and positive results from other ongoing trials, including IMP761 and EFTISARC-NEO.
Read more →IMMPImmutep Receives Nasdaq Notice of Bid Price Deficiency
Immutep Limited has received a notice from Nasdaq regarding its failure to meet the minimum bid price requirement of $1.00 per share. The company has a compliance period of 180 days to regain this status. While the notification does not affect current trading, there is uncertainty about whether compliance will be achieved within the given timeframe.
Read more →IMMPImmutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Immutep Limited announced that an abstract has been accepted for presentation at the ASCO 2026 Annual Meeting. The abstract focuses on the impact of eftilagimod alfa on lymphocyte activation and survival outcomes in metastatic cancer patients. The presentation will showcase data linking immune activation markers to improved survival rates. The event will take place from May 29 to June 2, 2026, in Chicago.
Read more →IMMP▲ +72.8%on this news
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
Immutep Limited has received FDA Orphan Drug Designation for eftilagimod alfa to treat Soft Tissue Sarcoma, a rare cancer. This designation supports the development of therapies for rare diseases and provides potential regulatory benefits. The decision is backed by promising results from the Phase II EFTISARC-NEO trial, which demonstrated significant efficacy in tumor response.
Read more →IMMPImmutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
Immutep has successfully completed the single ascending dose portion of its Phase I study for IMP761, a LAG-3 agonist aimed at treating autoimmune diseases. The drug was well tolerated with no safety concerns reported. The study is now progressing to the multiple ascending dose phase, with results to be presented at the EULAR conference in June 2026.
Read more →IMMP▼ -82.4%on this newsshared move
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
Immutep Limited has announced the discontinuation of the TACTI-004 Phase III study evaluating eftilagimod alfa in first-line non-small cell lung cancer. The Independent Data Monitoring Committee recommended this decision following a futility analysis. Despite this setback, Immutep plans to continue developing its pipeline and reassess its capital allocation priorities.
Read more →IMMPIMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2025 (previous corresponding period: half-year ended 31 December 2024) To be read in conjunction with the 30 J
Immutep Limited reported its half-year financial results for the period ending December 31, 2025. The company experienced a net loss after tax of A$44,859,721, a significant increase compared to the previous year's loss. Total revenues increased by 6%, but a marked decline in other income, alongside decreased net tangible assets per share, raises concerns about the company's financial health. Despite the losses, Immutep reported positive developments in its clinical trials for efti, particularly in key oncology indications.
Read more →IMMPImmutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
Immutep Limited has reached 50% enrolment in the TACTI-004 Phase III trial, which evaluates eftilagimod alfa in combination with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer. The trial aims to establish a new standard of care and has enrolled 378 patients across 27 countries. The company anticipates completing enrolment by Q3 2026.
Read more →IMMP▼ -8.1%on this news
Immutep Quarterly Activities Report & Appendix 4C Q2 FY26
Immutep Limited has reported significant progress in its Q2 FY26 Quarterly Activities Report, primarily highlighting a strategic collaboration with Dr. Reddy's for the commercialization of eftilagimod alfa (efti) outside North America. The collaboration includes an upfront payment and potential milestone payments, indicating strong financial prospects. Additionally, the company detailed the ongoing progress of its Phase III TACTI-004 trial, which shows promise in treating advanced non-small cell lung cancer. Furthermore, data from various trials, including INSIGHT-003 and EFTISARC-NEO, demonstrate encouraging efficacy and safety profiles for efti.
Read more →IMMPImmutep Quarterly Activities Report Q2 FY26
Immutep Limited has reported significant advancements in its Q2 FY26 activities, including a strategic collaboration with Dr. Reddy's for the development of efti, a novel immunotherapy. The company is making strong progress in its Phase III TACTI-004 trial for non-small cell lung cancer and has received positive feedback from the FDA regarding efti's dosing. However, the INSIGHT-005 Phase I study was discontinued due to recruitment difficulties.
Read more →About Immutep Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next IMMP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime